Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
Details : The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Efbemalenograstim Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evive Biotech meets Promising Results at Global Ph III Trial for Neutropenia Treatment
Details : Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF . F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care.
Product Name : F-627
Product Type : Protein
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Efbemalenograstim Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable